Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

By continuing you agree to the terms and privacy policy.

Welcome — one more step

News Plus opens the cross-newsroom layer — who covered a story, who didn’t, and how each one worded it.

  • Unlimited follows
  • Alerts for what you follow (in the app)
  • Story alerts (in the app)
  • Hide read stories (in the app)
  • The daily brief by email
  • Headlines side by side
  • Who reported first
  • The whole archive
  • Your reading diet
  • Duki without the monthly limit

Eligible new subscribers get 7 days free, then $34.99 each year. Renews automatically until cancelled. Cancel any time in your account. Subscription terms.

Your subscription also unlocks the app.

Download on theApp StoreGet it onGoogle Play

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Live Terminal
Economy · Full coverage

Sofwave Medical Aesthetics Secures Chinese Market Approval for Flagship Product

How 2 Israeli newsrooms covered this story — translated into English and compared side by side.

Unrated 2

By אמיר פרגר

First reported by Bizportal · 4 hours ago

What happened

Israeli medical aesthetics company Sofwave has received regulatory approval from China's NMPA to market its flagship skin rejuvenation device. This opens up a significant new market for the company, which has seen recent financial recovery and stock price appreciation, despite past challenges.

  • 01Sofwave received Chinese regulatory approval to market its flagship skin treatment device.
  • 02The approval allows entry into China's large and growing non-invasive aesthetics market.
  • 03The company partnered with HTDK for exclusive distribution in China.
  • 04Sofwave has experienced recent financial growth and stock market recovery.
  • 05The company's main market is North America, with East Asia as a secondary focus.

Summary translated & synthesized from the sources below by baba. Read each original for the full report.

In this story
People
OrganizationsSofwave, National Medical Products Administration (NMPA), HTDK, U.S. Food and Drug Administration (FDA), Israel Securities Authority
PlacesChina, United States, North America, East Asia, South Korea, Japan, Australia, Yokneam

Full coverage · 2 outlets

The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.

CalcalistUnrated · Hebrew2 hours ago
Sofwave Medical Aesthetics Secures Chinese Market Approval for Flagship Product
BizportalUnrated · Hebrew4 hours ago
Sofwave Gains Chinese Market Approval for Non-Invasive Aesthetic Treatments

Related stories

SupWave Medical Rises as Rare Success Story on Tel Aviv Stock ExchangeAug 24, 2026Israeli Companies Announce Medical Breakthroughs and InvestmentsSep 8, 2026Sofwave Reports Fifth Consecutive Profitable Quarter, CEO to Receive $4.3 Million in Stock UnitsAug 4, 2026FDA-Cleared Home Ultrasound Device Paves Plasanmor’s Entry Into the U.S. MarketJun 24, 2026France Pushes New Rules for Aesthetic Medicine Advertising as Israel Faces Similar ChallengesAug 24, 2026China Approves Weight Loss Drug Wegovy for Fatty Liver Disease TreatmentSep 14, 2026